PE20190630A1 - Anticuerpos de anti-tim-3 - Google Patents

Anticuerpos de anti-tim-3

Info

Publication number
PE20190630A1
PE20190630A1 PE2019000397A PE2019000397A PE20190630A1 PE 20190630 A1 PE20190630 A1 PE 20190630A1 PE 2019000397 A PE2019000397 A PE 2019000397A PE 2019000397 A PE2019000397 A PE 2019000397A PE 20190630 A1 PE20190630 A1 PE 20190630A1
Authority
PE
Peru
Prior art keywords
seq
amino acids
sequence
whose
refers
Prior art date
Application number
PE2019000397A
Other languages
English (en)
Spanish (es)
Inventor
Carmine Carpenito
Yiwen Li
Yang Shen
Yi Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20190630A1 publication Critical patent/PE20190630A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2019000397A 2016-08-25 2017-08-17 Anticuerpos de anti-tim-3 PE20190630A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379343P 2016-08-25 2016-08-25
US201762469753P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
PE20190630A1 true PE20190630A1 (es) 2019-04-26

Family

ID=59772703

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000397A PE20190630A1 (es) 2016-08-25 2017-08-17 Anticuerpos de anti-tim-3

Country Status (26)

Country Link
US (1) US10253096B2 (zh)
EP (1) EP3504240B1 (zh)
JP (1) JP6502590B1 (zh)
KR (1) KR102142903B1 (zh)
CN (1) CN109563172B (zh)
AU (1) AU2017316473B2 (zh)
BR (1) BR112019001589A2 (zh)
CA (1) CA3035042A1 (zh)
CL (1) CL2019000488A1 (zh)
CO (1) CO2019001646A2 (zh)
CR (1) CR20190079A (zh)
DO (1) DOP2019000027A (zh)
EC (1) ECSP19013181A (zh)
ES (1) ES2908916T3 (zh)
IL (1) IL264159A (zh)
JO (1) JOP20190013A1 (zh)
MA (1) MA46041A (zh)
MX (1) MX2019002064A (zh)
PE (1) PE20190630A1 (zh)
PH (1) PH12019500369A1 (zh)
SG (1) SG11201900480YA (zh)
TN (1) TN2019000040A1 (zh)
TW (2) TWI639616B (zh)
UA (1) UA122929C2 (zh)
WO (1) WO2018039020A1 (zh)
ZA (1) ZA201900373B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2768784T3 (es) 2015-03-23 2020-06-23 Bayer Pharma AG Anticuerpos anti-CEACAM6 y usos de los mismos
PL3443009T3 (pl) 2016-04-12 2022-01-31 Symphogen A/S Przeciwciała i kompozycje anty-tim-3
CA3030765A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
WO2018106529A1 (en) * 2016-12-08 2018-06-14 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
CN112543647B (zh) * 2018-08-28 2024-04-16 江苏恒瑞医药股份有限公司 一种tim3抗体药物组合物及其用途
CN113301961A (zh) * 2018-11-01 2021-08-24 默克专利有限公司 给予抗tim-3抗体的方法
WO2020093023A1 (en) * 2018-11-01 2020-05-07 Merck Patent Gmbh Anti-tim-3 antibodies
CA3123735A1 (en) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
CA3126133A1 (en) * 2019-01-11 2020-07-16 Eli Lilly And Company Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
WO2021051352A1 (zh) * 2019-09-19 2021-03-25 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody preparations and methods of using them
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2023031366A1 (en) 2021-09-02 2023-03-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
EP2417984B1 (en) * 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016007513A1 (en) 2014-07-07 2016-01-14 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
WO2016068803A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
RU2723708C2 (ru) * 2014-11-06 2020-06-17 Ф.Хоффманн-Ля Рош Аг Анти-tim3 антитела и способы их применения
US10822414B2 (en) * 2014-11-11 2020-11-03 Sutro Biopharma, Inc. Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
CN104592388B (zh) * 2015-03-02 2017-05-31 中国人民解放军总医院 一种抗人Tim‑3的单克隆抗体的抗原结合部分
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
WO2018106529A1 (en) * 2016-12-08 2018-06-14 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
TW201900684A (zh) 2019-01-01
ES2908916T3 (es) 2022-05-04
SG11201900480YA (en) 2019-02-27
US20180057591A1 (en) 2018-03-01
MX2019002064A (es) 2019-06-06
UA122929C2 (uk) 2021-01-20
AU2017316473A1 (en) 2019-01-31
CR20190079A (es) 2019-04-08
EP3504240A1 (en) 2019-07-03
TN2019000040A1 (en) 2020-07-15
CO2019001646A2 (es) 2019-03-08
TW201819419A (zh) 2018-06-01
NZ749820A (en) 2021-05-28
CN109563172A (zh) 2019-04-02
US10253096B2 (en) 2019-04-09
ZA201900373B (en) 2020-10-28
TWI639616B (zh) 2018-11-01
JOP20190013A1 (ar) 2019-01-31
EP3504240B1 (en) 2022-02-16
IL264159A (en) 2019-02-28
JP2019517999A (ja) 2019-06-27
CA3035042A1 (en) 2018-03-01
KR102142903B1 (ko) 2020-08-11
MA46041A (fr) 2021-03-24
CN109563172B (zh) 2022-02-08
BR112019001589A2 (pt) 2019-07-09
AU2017316473B2 (en) 2019-12-19
PH12019500369A1 (en) 2019-11-25
CL2019000488A1 (es) 2019-07-12
ECSP19013181A (es) 2019-03-29
WO2018039020A1 (en) 2018-03-01
DOP2019000027A (es) 2019-03-15
JP6502590B1 (ja) 2019-04-17
KR20190031528A (ko) 2019-03-26

Similar Documents

Publication Publication Date Title
PE20190630A1 (es) Anticuerpos de anti-tim-3
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
NZ731735A (en) Anti-pd-1 antibodies and methods of use thereof
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos